Lilly Playing Catch Up In Oncology

25 May 2016

• By Lisa LaMotta

The big pharma is chasing the competition in multiple areas of oncology, bringing forward offerings in CDK 4/6, as well as PD-L1.

Eli Lilly & Co. may be known for its leadership in the diabetes space, but the Indianapolis pharma is quietly building up its presence in oncology hoping one day this franchise will be just as prominent. During an investor event with stakeholders on May 24, Lilly laid out its oncology strategy.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Can European Biotech Survive And Thrive In Era Of Instability?

30 Apr 2025

• By Andrew McConaghie

Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.